What question did this study set out to answer?

This study aims to investigate the role of endothelial CARMIL1 in maintaining barrier integrity and its impact on inflammation in acute respiratory distress syndrome (ARDS).

May 20, 2026

B75-16 Carmil1 Plays A Critical Role In Endothelial Barrier Function And Inflammation

Key Points

This study aims to investigate the role of endothelial CARMIL1 in maintaining barrier integrity and its impact on inflammation in acute respiratory distress syndrome (ARDS).
Assessed endothelial barrier function using a FITC-dextran transwell assay.
Examined CARMIL1 expression manipulation via lentiviral transduction and siRNA knockdown.
Measured inflammatory markers (IL-6, IL-8) using ELISA after various treatments.
CARMIL1 silencing reduced barrier integrity at baseline (884.1 ±34 vs 1409±26.8 A.U) and after thrombin treatment (1305.1 ±33.07 vs 1771.5±62.8 A.U).
CARMIL1 overexpression significantly decreased IL-6 levels after LPS treatment (1216.2±227.1 vs 829.16±141.01 pg/ml, P < 0.05).
CARMIL1 expression was associated with elevated levels of tight junction proteins ZO-1, claudin-5, and occludin.

Abstract

Abstract Rationale The acute respiratory distress syndrome (ARDS) results in alveolar edema, respiratory failure and high mortality. A dysfunctional pulmonary endothelial cell (EC) barrier is a key pathologic hallmark of ARDS. Protein regulation of the actin cytoskeleton is key to maintaining this barrier. We have previously identified a role for the cytoskeletal regulator capping protein Arp2/3 complex myosin-I linker (CARMIL1). In the present study, we link endothelial CARMIL1 expression to alterations in cell junctional proteins and markers of inflammation. Methods EC barrier function was assessed by a FITC-dextran transwell assay. CARMIL 1 expression was augmented in human pulmonary artery ECs via transduction with lentiviral particles encoding WT CARMIL1 or treatment with CARMIL1 siRNA (Santa Cruz) x 48 hrs. ECs were treated with sphingosine-1-phosphate (S1P) x 10 minutes, thrombin (1U/ml) or LPS x 18 hrs. Inflammatory markers (IL-6 and IL-8) were measured by ELISA. Cell fractions (membrane vs cytosol) were separated by differential centrifugation. CARMIL1 and junctional protein expression levels were quantified by western blot. Results CARMIL1 silenced cells exhibited reduced barrier integrity at baseline (884.1 ±34v 1409±26.8 (A.U) and following thrombin (1305.1 ±33.07vs 1771.5±62.8 (A.U) as measured by the FITC-dextran permeability assay. Reduced CARMIL1 expression results in decreased expression of the tight junction proteins ZO-1, claudin-5 and occludin. After LPS treatment, cells transduced with CARMIL1 had significantly decreased levels of IL-6 compared to vector (1216.2±227.1 vs 829.16± 141.01pg/ml, P 0.05) and a trend in reduced IL-8 (11277.2±1767.1 vs9488±1186.254pg/mL). We observed increased CARMIL1 translocation to the cell membrane following S1P treatment. Conclusion Endothelial CARMIL1 expression is required for baseline barrier integrity and preserves barrier function after inflammatory stimuli. CARMIL1 overexpression reduces EC inflammatory markers. Alterations in junctional proteins offer a mechanistic explanation for the role of endothelial CARMIL1 in pulmonary vascular leak and ARDS outcomes. This abstract is funded by: NIH 1R01HL170118

Bookmark

Cite This Study

Chen et al. (Fri,) studied this question.

synapsesocial.com/papers/6a0d4fd2f03e14405aa9b595 https://doi.org/https://doi.org/10.1093/ajrccm/aamag162.127

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark